Horizon Pharma shares offer 'significant value,' says Stifel Stifel sees "significant value" in shares of Horizon Pharma with today's pullback and it keeps a Buy rating on the name. The firm says Express Scripts and Caremark putting Duexis and Vimovo on their exclusion lists is a "large disappointment," but it believes management has several avenues to offset the impact. Stifel lowered its price target for shares to $20 from $25.
Horizon Pharma's Actimmune Phase 2 results provide more growth, says Avondale Avondale said Horizon Pharma's Actimmune Phase 2 results were strong and support incremental annual market opportunity of approximately $300K per year. The firm views the results as another potential growth driver and its Outperform rating and $22 price target.